GPX4 and Alzheimer disease: The metal ion chelator deferoxamine (DFO) is shown to inhibit the accumulation of iron in the brain tissues of AD animals, followed by the reduction of Aβ plaque formation (46), suggesting that targeting ferroptosis-related pathways, such as iron metabolism, lipid metabolism, and the GPX4 antioxidant system, could be a promising therapeutic breakthrough for AD (19).